Last reviewed 2026-04-23 · How we verify

MP-513

MP-513 is a selective antagonist of the complement C5a receptor that inhibits complement-mediated inflammation.

MP-513 is a selective antagonist of the complement C5a receptor that inhibits complement-mediated inflammation. Used for IgA nephropathy, C3 glomerulopathy.

At a glance

Mechanism of action

MP-513 blocks the C5a receptor on immune cells, preventing the recruitment and activation of neutrophils and other inflammatory cells downstream of complement cascade activation. This mechanism reduces tissue damage and inflammation in complement-driven diseases, particularly those affecting the kidney and other organs.

Approved indications

• IgA nephropathy
• C3 glomerulopathy

Common side effects

• Nasopharyngitis
• Headache
• Diarrhea

Key clinical trials

• Long-Term Safety Study of MT-2412 in Japanese Patients With Type 2 Diabetes (PHASE3)
• Efficacy and Safety of MP-513 in Combination With Metformin in Patients With Type 2 Diabetes (PHASE2)
• Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Canagliflozin) (PHASE3)
• Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Teneligliptin) (PHASE3)
• Efficacy and Safety Study of MP-513 in Combination With Sulfonylurea in Patients With Type 2 Diabetes (PHASE3)
• Efficacy and Safety Study of MP-513 in Combination With Thiazolidinedione in Patients With Type 2 Diabetes (PHASE3)
• Long-term Safety Study of MP-513 as Monotherapy or in Combination With Sulfonylurea in Japanese Type 2 Diabetic Patients (PHASE3)
• Efficacy and Safety Study of MP-513 in Patients With Type 2 Diabetes (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.